Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-621 in Moderate to Severe Atopic Dermatitis (Phase 2b, Japan)
jRCT2031250674Phase 2Active, not recruiting
- Sponsor
- Kymera Therapeutics
- Start
- Mar 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing KT-621 with Placebo / KT-621 open-label (2 arms). Primary endpoint: Percent change from baseline to Week 16 in EASI score. Started Mar 2026; status: active, not recruiting.
02
Drugs
KT-621
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031250674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250674.